"Pharmaceutical Speed ​​Reading Club" State Office Announces New Crown Vaccine Charges, Hengrui Li Yuan, Resigns at the Expiration of His Term

【2021420/】；；bemarituzumabFDA……，！

Part 1

Part 1 Part 1

？！

？！

19，，“+”，，，“”。（）

，，。，812。，5，。（）

Part 2

Part 2 Part 2

Johnson & Johnson, AbbVie, Teva and Endo face $50 billion opioid lawsuits

Johnson & Johnson, AbbVie, Teva and Endo face $50 billion opioid lawsuits

According to foreign media reports, Johnson & Johnson, AbbVie's Allergan, Teva Pharmaceuticals and Endo will face a virtual trial because they are accused of diluting the risk of opioid addiction in order to promote the development of this powerful painkiller.

Hengrui Pharmaceutical's independent director Li Yuanchao resigns after his term of office expires

Hengrui Pharmaceutical's independent director Li Yuanchao resigns after his term of office expires

Hengrui Medicine issued an announcement stating that in accordance with the relevant provisions of the "Guiding Opinions on Establishing an Independent Director System in Listed Companies", "Articles of Association of Jiangsu Hengrui Pharmaceutical Co.

Adagio receives US$336 million to assist the development of "broad-spectrum" new coronavirus neutralizing antibodies

Adagio receives US$336 million to assist the development of "broad-spectrum" new coronavirus neutralizing antibodies

Adagio Therapeutics announced today that it has completed a $336 million Series C financing led by RA Capital Management.

Part 3 Drug News

Part 3 Drug News Part 3 Drug News Information

Subcutaneous RNAi therapy reaches all phase 3 clinical endpoints

Subcutaneous RNAi therapy reaches all phase 3 clinical endpoints

Today, Alnylam Pharmaceuticals announced that vutrisiran, a subcutaneous RNAi therapy developed by the company, has reached the primary endpoint and all secondary endpoints in a phase 3 clinical trial for the treatment of patients with hereditary transthyretin (hATTR) amyloidosis.

Amgen bemarituzumab receives FDA breakthrough therapy designation

Amgen bemarituzumab receives FDA breakthrough therapy designation

Today, Amgen announced that the US FDA has granted its research FGFR2b antibody therapy bemarituzumab a breakthrough therapy designation, combined with chemotherapy, for the first-line treatment of patients with HER2-negative locally advanced or metastatic gastric cancer and gastroesophageal junction cancer.

Once a week long-acting GLP-1 analog Novo Nordisk's new diabetes drug enters "pending approval"

Once a week long-acting GLP-1 analog Novo Nordisk's new diabetes drug enters "pending approval"

On the 19th, the results of the NMPA drug registration progress query showed that the status of the new drug listing application for simeglutide injection submitted by Novo Nordisk has been updated to "pending approval".

Henri Carrelizumab is about to be approved for new indications for nasopharyngeal carcinoma

Henri Carrelizumab is about to be approved for new indications for nasopharyngeal carcinoma

The official website of NMPA shows that carrelizumab combined with cisplatin and gemcitabine is used for the indications of the application for the marketing of advanced nasopharyngeal carcinoma patients who have undergone second-line and above chemotherapy or have advanced or intolerable advanced nasopharyngeal carcinoma (acceptance number: CXSS2000045).

Hengrui Pharmaceuticals Ivabradine Hydrogen Sulfate Sustained-Release Tablets Approved for Clinical Trial

Hengrui Pharmaceuticals Ivabradine Hydrogen Sulfate Sustained-Release Tablets Approved for Clinical Trial

Hengrui Pharmaceuticals issued an announcement stating that it has recently received approval from the State Food and Drug Administration to issue a "Drug Clinical Trial Approval Notice" for ivabradine hydrogen sulfate sustained-release tablets, and clinical trials will be launched in the near future.

For adult lupus nephritis, Hengrui Pharmaceutical's subsidiary SHR-1314 injection was approved for clinical use

For adult lupus nephritis, Hengrui Pharmaceutical's subsidiary SHR-1314 injection was approved for clinical use

Hengrui Pharmaceuticals issued an announcement stating that its subsidiary Suzhou Shengdia Biopharmaceutical Co.

Nuocheng Jianhua RTK inhibitor ICP-033 new drug research application was accepted by the State Food and Drug Administration

Nuocheng Jianhua RTK inhibitor ICP-033 new drug research application was accepted by the State Food and Drug Administration

Nuocheng Jianhua announced today that the company's new multi-target receptor tyrosine kinase inhibitor ICP-033 new drug research application has been accepted by the State Food and Drug Administration.

Microcore Bio-Cidabenamine Lung Cancer Phase 2 Clinical Accepted, Cioroni Approved in China and the U.

Microcore Bio-Cidabenamine Lung Cancer Phase 2 Clinical Accepted, Cioroni Approved in China and the U.

Dongyang Sunshine Subsidiary Received Drug Registration Certificate for Escitalopram Oxalate Tablets

Dongyang Sunshine Subsidiary Received Drug Registration Certificate for Escitalopram Oxalate Tablets

Dongyang Sunshine announced that its subsidiary, Dongguan Yangzhikang Pharmaceutical Co.

Yangtze River Pharmaceutical's "Rigofinil Tablets" Launched on the First Domestic Newspaper

Yangtze River Pharmaceutical's "Rigofinil Tablets" Launched on the First Domestic Newspaper

According to the official website of CDE, Yangtze River's 4-category generic drug "Rigofinil Tablets" has been applied for listing (acceptance number: CYHS2101075), which is the first generic drug reported for listing in China.

PI3K dual inhibitor! New anti-cancer drugs introduced by CSPC are declared for listing in China

PI3K dual inhibitor! New anti-cancer drugs introduced by CSPC are declared for listing in China

CSPC announced that its subsidiary CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co.

Sanofi Sarclisa's combination of carfilzomib and dexamethasone is approved in the EU for the treatment of MM

Sanofi Sarclisa's combination of carfilzomib and dexamethasone is approved in the EU for the treatment of MM

The European Commission approved Sanofi Sarclisa (isatuximab, ixatuximab) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with recurrent multiple myeloma (MM) who have received at least one treatment treatment.